Double Bond Pharmaceutical has during the summer carried out and completed a successful collaborative project with the In vitro and Systems Pharmacology unit within the SciLifeLab Drug Discovery and Development platform.
The goal was to deepen the knowledge about the pharmacological and cytotoxic effects of the drug Temodex in vitro in different human brain cancer cell lines. Temodex is a locally acting formulation of temozolomide that is the present first line of treatment of glioblastoma in Belarus. The drug is currently subjected to all studies and trials needed for it to become registered in the EU and globally.
The study conducted at SciLifeLab shows that temozolomide itself not only is cytotoxically active against glioblastoma tumors but also against other types of brain tumors, such as medulloblastoma and metastases from other primary tumors. This suggests that the indications for Temodex could potentially be broadened.
Read the press release published by the Uppsala-based Double Bond Pharmaceutical on September 4.